Sentagliptin Phosphate - single dose

Phase 3Small molecule

SSecond Affiliated Hospital of Soochow University

Sentagliptin Phosphate - single dose is one of 48 small molecule programs targeting Cognitive impairment. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cognitive ImpairmentActive, not recruiting

Cognitive ImpairmentPhase 3

Active, not recruiting

Competition

Competitive Landscape

279 competitors in Cognitive Impairment

#DrugCompanyPhaseTrials

Actos

Takeda

Phase 3

3 2

Farxiga

AstraZeneca

Phase 3

1 3

Provigil

NNuvo Research GmbH

Phase 3

1 4

Xarelto

WWim Janssens

Phase 3

1 5

Aquasol E

NNational Eye Institute (NEI)

Phase 3

1 6

Viagra

VViatris Specialty LLC

Phase 3

1 7

Donepezil Hydrochloride

Eisai

Phase 3

3 8

Statins

Sanofi

Phase 3

1 9

Nicorette

Pfizer

Phase 2

2 10

Galantamine Hydrobromide

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2028

Phase 3Not yet recruiting

Cognitive Impairment

NCT07241897

Clinical

Trials by Indication[1]

Cognitive impairment1 trial

DPP4 Inhibitor Intervention on Post-stroke Cognitive Impairment in Ischemic Stroke Patients With Type 2 Diabetes

Not yet recruiting·SSecond Affiliated Hospital of Soochow University·Phase 3·NCT07241897·312 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Sentagliptin Phosphate - single dose. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Sentagliptin Phosphate - single dose compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Sentagliptin Phosphate - single dose. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Affiliated Hospital of Soochow University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SSecond Affiliated Hospital of Soochow University

Sentagliptin Phosphate - single dose

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2028

Trials by Indication[1]

Cognitive impairment1 trial

References

Drug Info

Quick Facts

Related News